Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids JACC Focus Seminar

被引：41
作者：
Weinberg, Richard L. [1 ]
Brook, Robert D. [2 ]
Rubenfire, Melvyn [1 ]
Eagle, Kim A. [1 ]
机构：
[1] Univ Michigan, Dept Internal Med, Michigan Med, Div Cardiovasc Med,Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA
[2] Wayne State Univ, Div Cardiol, Detroit, MI USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 77卷 / 05期
关键词：
docosahexaenoic acid; eicosapentaenoic acid; fish oil; omega-3 fatty acids; N-3; FATTY-ACIDS; FISH-OIL SUPPLEMENTS; RANDOMIZED CONTROLLED-TRIAL; HIGH TRIGLYCERIDE LEVELS; CORONARY-HEART-DISEASE; ESTER AMR101 THERAPY; EICOSAPENTAENOIC ACID; ICOSAPENT ETHYL; PRESCRIPTION OMEGA-3-FATTY-ACIDS; HYPERCHOLESTEROLEMIC PATIENTS;
D O I：
10.1016/j.jacc.2020.11.060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Omega-3 polyunsaturated fatty acids (PUFAs) are a key component of a heart-healthy diet. For patients without clinical atherosclerotic cardiovascular disease, 2 or more servings of fatty fish per week is recommended to obtain adequate intake of omega-3 PUFAs. If this not possible, dietary supplementation with an appropriate fish oil may be reasonable. Supplementation with omega-3 PUFA capsules serves 2 distinct but overlapping roles: treatment of hypertriglyceridemia and prevention of cardiovascular events. Marine-derived omega-3 PUFAs reduce triglycerides and have pleiotropic effects including decreasing inflammation, improving plaque composition and stability, and altering cellular membranes. Clinical trial data have shown inconsistent results with omega-3 PUFAs improving cardiovascular outcomes. In this paper, the authors provide an overview of PUFAs and a summary of key clinical trial data. Recent trial data suggest the use of prescription eicosapentaenoic acid ethyl ester for atherosclerotic cardiovascular disease event reduction in selected populations. (C) 2021 by the American College of Cardiology Foundation.
引用
收藏
页码：593 / 608
页数：16
相关论文
共 96 条
[1]  
Agricultural Research Service U.S. Department of Agriculture, FOODDATA CENTR
[2]  
Albert BB, 2016, SCI REP-UK, V6, DOI [10.1038/srep35092, 10.1038/srep07928]
[3]  
[Anonymous], 2019, FDA BRIEF DOC END ME
[4]   Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies [J].
Ballantyne, Christie M. ;
Bays, Harold E. ;
Braeckman, Rene A. ;
Philip, Sephy ;
Stirtan, William G. ;
Doyle, Ralph T., Jr. ;
Soni, Paresh N. ;
Juliano, Rebecca A. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (03) :635-645
[5]   Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study) [J].
Ballantyne, Christie M. ;
Braeckman, Rene A. ;
Bays, Harold E. ;
Kastelein, John J. ;
Otvos, James D. ;
Stirtan, William G. ;
Doyle, Ralph T., Jr. ;
Soni, Paresh N. ;
Juliano, Rebecca A. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (03) :377-383
[6]   Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) [J].
Ballantyne, Christie M. ;
Bays, Harold E. ;
Kastelein, John J. ;
Stein, Evan ;
Isaacsohn, Jonathan L. ;
Braeckman, Rene A. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (07) :984-992
[7]  
Barnes Patricia M, 2008, Natl Health Stat Report, P1
[8]   Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies [J].
Bays, Harold E. ;
Ballantyne, Christie M. ;
Braeckman, Rene A. ;
Stirtan, William G. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (01) :37-46
[9]   Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) [J].
Bays, Harold E. ;
Braeckman, Rene A. ;
Ballantyne, Christie M. ;
Kastelein, John J. ;
Otvos, James D. ;
Stirtan, William G. ;
Soni, Paresh N. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (06) :565-572
[10]   Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) [J].
Bays, Harold E. ;
Ballantyne, Christie M. ;
Kastelein, John J. ;
Isaacsohn, Jonathan L. ;
Braeckman, Rene A. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (05) :682-690
12345678910